INTRODUCTION
Recombinant activated factor VII (rFVIIa) is increasingly being given on a compassionate basis to control severe bleeding 1 and has been shown to result in a significant reduction in red blood cell transfusion in severe blunt trauma. 2 Although consensus guidelines for use of rFVIIa have been published recently, 3 ,4 a paucity of data from randomized controlled trials limit the strength and scope of these recommendations. No specific method is currently available to indicate the need for rFVIIa or to monitor its efficacy. Therefore, the administration of rFVIIa in patient with massive hemorrhage still depends largely on clinical judgment. 5 Viscoelastic techniques like thrombelastography/thrombelastometry or Sonoclot analysis appear to be highly desirable and have shown some promising results. [6] [7] [8] Coagulation is assessed in whole blood allowing coagulation factors to interact with red cells and platelets. rFVIIa increases thrombin formation by tissue factor dependent and -independent activation of factor X on the surface of platelets. 9 To study effects of rFVIIa, blood samples need to be activated with minute amounts of tissue factor for best sensitivity. 10, 11 Presence of high amounts of tissue factor may directly activate the coagulation cascade (bypassing agent) and effects of rFVIIa may no longer be monitored. 11 Modern practice of coagulation management is based on rapid diagnosis of the patient's coagulation status, specific component therapy, and monitoring of the procoagulant treatment. 12 Measuring clotting factors during progressive hemodilution showed that fibrinogen is the first factor to become critically low. 13, 14 Fibrinogen is a key coagulation factor (substrate to form a clot) and isolated fibrinogen substitution in severe 5 models of dilutional coagulopathy resulted in a significantly improved clot strength and reduced blood loss. [15] [16] [17] [18] The aim of this in vitro study was to determine the efficacy of rFVIIa in a model of severe dilutional coagulopathy by two different viscoelastic point of care (POC) coagulation analyzers (ROTEM system, Pentapharm GmbH, Munich, Germany and the Sonoclot Analyzer, Sienco Inc. Arvada, CO, USA). Our hypothesis was that rFVIIa may only reverse severe dilutional coagulopathy in presence of sufficient fibrinogen levels.
METHODS
With institutional approval blood was withdrawn from 10 healthy volunteers.
Exclusion criteria were hereditary or acquired coagulation disorders including pharmacologically induced coagulopathies i.e., treatment with any anticoagulants or antiplatelet drugs 14 days before blood withdrawal.
Blood Sampling
Fifty millilitres of venous blood were sampled after application of minimum stasis from the antecubital fossa via a 21-gauge needle. The blood was filled into citrated tubes (sodium citrate, 0.109 mol/l; BD Vacutainer, Becton Dickinson) and the initial tube was discarded before collection of the test tubes to avoid tissue factor contamination. An extra tube (EDTA; BD Vacutainer, Becton Dickinson) was obtained for whole blood count and platelet measurement.
Hemodilution
In order to mimic a scenario of maximum dilution of clotting factors but maintaining a minimally required hemoglobin concentration and platelet count, we processed our 6 samples to obtain platelet-rich plasma (PRP; centrifugation at 80 g for 8 min 
Treatment of hemodiluted blood samples with rFVIIa and fibrinogen
The reconstituted blood samples were treated with a therapeutic dose of rFVIIa alone or combined with rFVIIa. Because the maximum effect of rFVIIa was seen in blood samples treated with fibrinogen, a dose response of rFVIIa was then performed in these blood samples.
Coagulation Analysis
Whole blood coagulation analyses were done with the rotation thrombelastometry ROTEM (Pentapharm GmbH, Munich, Germany) and the Sonoclot Coagulation and Platelet Function Analyzer (Sienco Inc. Arvada, CO, USA). Both technologies have been described in detail elsewhere. 21, 22 Briefly, the measurements are based on the detection 7 of viscoelastic changes of a blood sample after activation with different coagulation activators (1:1,000 diluted tissue factor was used for this study).
ROTEM measures and graphically displays the time until initial fibrin formation (clotting time, CT: denoted as clot initiation), the kinetics of fibrin formation and clot development (alpha angle, α: denoted as clot propagation) and the ultimate clot strength and stability (maximum clot firmness, MCF). 16, [23] [24] [25] In order to study thrombus generation, modified ROTEM parameters (based on the original tracing) have been introduced recently: maximum velocity of clot formation (maximum rate of thrombus generation, MaxVel), time to reach MaxVel (time to maximum thrombus generation, tMaxVel) and total thrombus generation (area under the curve, AUC). 11, 23 These parameters are supposed to be more sensitive to rFVIIa than standard ROTEM parameters. 26 The Sonoclot Analyzer provides information on the entire hemostasis process both in a qualitative graph, known as Sonoclot Signature and as quantitative results: the activated clotting time (ACT), the clot rate (CR) and the platelet function. The ACT is the time from the activation of the sample until the beginning of a fibrin formation.
Besides providing information on the initiation phase of coagulation, the Sonoclot Analyzer also measures the kinetics of fibrin formation and clot development, expressed as CR (i.e., the maximum slope of the Sonoclot Signature during initial fibrin polymerization and clot development). Furthermore, the Sonoclot Analyzer analyses the timing and quality of the clot retraction and calculates the function of the platelets accordingly. 25 All analyses were performed at 37°C in duplicate using 1:1,000 diluted tissue factor activated tests provided by the manufacturer (for ROTEM: tif-TEM, Pentapharm GmbH, Munich, Germany; for Sonoclot: microPT, Sienco Inc., Arvada, CO, USA). Re- 
RESULTS
Venous blood was obtained from 10 male donors (age = 35.5±7.5 years). They were non-smokers, had no history of abnormal bleeding and presented without a coagulation disorder or anemia ( Table 1) .
In-vitro hemodilution
Diluting blood samples according to our model resulted in a final hematocrit of 19% on average and significantly impaired standard coagulation values ( Table 1) . ROTEM 9 and Sonoclot variables reflected the severe hemodilution: ROTEM's CT and t-MaxVel significantly increased, whereas all other variables (angle α, MCF, MaxVel and AUC) significantly decreased. The same effect was observed for the Sonoclot variables ACT and CR (Figure 1,2) . ACT and CR (Figure 1,2) .
Effect of rFVIIa and fibrinogen on hemodiluted blood samples

Dose response of rFVIIa
Because administration of fibrinogen was necessary for rFVIIa to show an effect in our dilutional model, a dose response in samples containing fibrinogen was performed.
ROTEM's CT and Sonoclot's ACT improved equally in all doses studied, even at the lowest dose. ROTEM's angle α, MCF and Sonoclot's CR showed comparable results at half of the recommended dose compared to the recommended dose, but the procoagulant effect was lost at a quarter of the recommended dose. Again, the new ROTEM variables did follow the trend of the CT, angle α and MA ( Table 2) .
Test variability
Overall ROTEM test variability was 14±14% for CT, 9±11% for angle α, 10±12% for MCF, 13±14% for t-MaxVel, 9±13% for MaxVel and 10±16% for AUC.. For the Sonoclot Analyzer test variability was 9±18% for ACT and 10±18% for CR.
DISCUSSION
The present study investigated the effects of administration of rFVIIa and fibrinogen in an in vitro hemodilution model. The ROTEM and Sonoclot Analyzer were able to monitor the pro-coagulant effects of rFVIIa and fibrinogen administration with diluted tissue factor activated tests, tif-TEM and MicroPT. Interestingly, rFVIIa required high concentrations of fibrinogen in order to improve the severe coagulopathy.
In the initial period of fluid resuscitation of patients with massive hemorrhage, large amounts of crystalloids, colloids, and universal 0 type RBC are typically infused. Testing and preparing of blood coagulation products (e.g., fresh frozen plasma, cryoprecipitate, and platelets) is time consuming. Therefore, a severe dilutional coagulopathy may develop in the early period of massive transfusion because these coagulation products may not be readily available. Our dilutional model aimed at reproducing an extreme dilutional coagulopathy but keeping minimal hemoglobin and platelet levels ( recommended dose (~50 μg/kg, final concentration of 0.7 μg/ml) has similar effect as compared to the full dose. Further decreasing the administered dose however resulted in a loss of the pro-coagulant effect of rFVIIa.
Our data are in accordance with previously published reports showing that isolated rFVIIa administration has failed to correct coagulopathy in an in vitro model of hemodilution. 33 Furthermore, rFVIIa treatment has shown minimal effects on blood loss after major hemorrhage in animals with severe dilutional coagulopathy. 34, 35 The concept of rFVIIa is to activate coagulation at sites of tissue factor exposure. The resulting thrombin burst then leads to the formation of a fibrin clot, provided sufficient fibrinogen levels and platelets are present. In order to get the maximum effect of rFVIIa, consensus guidelines recommend first that the bleeding source should be controlled as best as possible and second that patients be optimized prior to administration of rFVIIa targeting a hematocrit >24%, fibrinogen >0.5-1 g/l, platelets >50-100,000 x 10 9 /l and pH ≥7.2.
3,4,32
In our dilutional model however, rFVIIa improved the coagulation status significantly even with lower platelets (32,000 x 10 9 /l) if prior fibrinogen substitution was performed.
ROTEM and the Sonoclot Analyzer are both viscoelastic POC coagulation analyzers. 
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